Patients with diffuse scleritis typically present with severe eye pain, which may radiate to the forehead, jaw, or sinuses. The eye often appears red and swollen, and patients may experience tearing and sensitivity to light (photophobia). Vision may be affected if the inflammation extends to other parts of the eye. Unlike episcleritis, a milder condition, the pain in scleritis is more intense and persistent.

The workup for diffuse scleritis involves a thorough clinical examination by an ophthalmologist. This includes a slit-lamp examination to assess the extent of inflammation. Blood tests may be conducted to identify underlying systemic conditions, such as autoimmune diseases, which are often associated with scleritis. Imaging studies, like ultrasound or MRI, may be used to evaluate the depth of scleral involvement and rule out other conditions.

Treatment for diffuse scleritis aims to reduce inflammation and address any underlying causes. Nonsteroidal anti-inflammatory drugs (NSAIDs) are often the first line of treatment. If NSAIDs are ineffective, corticosteroids may be prescribed. In cases linked to autoimmune diseases, immunosuppressive agents might be necessary. Regular follow-up is essential to monitor the response to treatment and adjust medications as needed.

The prognosis for diffuse scleritis varies depending on the underlying cause and the timeliness of treatment. With appropriate management, many patients experience significant relief from symptoms. However, if left untreated, scleritis can lead to complications such as vision loss, glaucoma, or cataracts. Early diagnosis and treatment are key to preventing these outcomes.

Diffuse scleritis is often associated with systemic autoimmune diseases, such as rheumatoid arthritis, lupus, or granulomatosis with polyangiitis. In some cases, it may be linked to infections or trauma. However, the exact cause remains unknown in a significant number of patients. Understanding the underlying etiology is crucial for effective management and treatment.

Scleritis is a relatively rare condition, with diffuse scleritis being one of its less common forms. It can occur at any age but is most frequently seen in adults between 30 and 60 years old. There is a slight female predominance, likely due to the higher prevalence of autoimmune diseases in women. The condition is seen worldwide, with no specific geographic or ethnic predilection.

The pathophysiology of diffuse scleritis involves an immune-mediated inflammatory response targeting the sclera. This response can be triggered by systemic autoimmune diseases, infections, or other factors. The inflammation leads to the breakdown of scleral tissue, causing pain and redness. Understanding these mechanisms is essential for developing targeted therapies.

Preventing diffuse scleritis involves managing underlying systemic conditions effectively. Regular monitoring and treatment of autoimmune diseases can reduce the risk of scleritis. Patients should also avoid eye trauma and seek prompt medical attention for any eye symptoms. While not all cases can be prevented, these measures can help reduce the incidence and severity of the condition.

Diffuse scleritis is a serious inflammatory condition of the eye that requires prompt diagnosis and treatment. It is often associated with systemic autoimmune diseases and presents with severe eye pain and redness. A comprehensive workup is necessary to identify underlying causes and guide treatment. With appropriate management, the prognosis is generally favorable, although complications can occur if left untreated.

If you are experiencing severe eye pain, redness, or vision changes, it is important to seek medical attention. Diffuse scleritis is a condition that affects the white part of the eye and can be associated with other health issues. Treatment is available and can help relieve symptoms and prevent complications. Regular check-ups and managing any underlying health conditions can also help reduce the risk of developing scleritis.